Swiss biotech Oculis has raised $21 million in a Series B round backed by investors including Novartis (NYSE:NVS) and Bay City Capital.
The company is developing topical drugs for back-of-the-eye diseases, which are normally treated with painful injections directly into the eye.
Get the full story at our sister site, Drug Delivery Business News.
The post Swiss biotech Oculis raises $21m for nanoparticle eye-drops appeared first on MassDevice.